PHLDA3

Across TCGA pan-cancer cohorts, PHLDA3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PHLDA3 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PHLDA3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PHLDA3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

CCRCC, GBM, and LUAD are the cancer types where PHLDA3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.910	1.000	.010	10	view →
GBM	DFS	Quartile	All	0.280	0.491	.012	10	view →
LUAD	DFS	Tertile	III,IV	0.566	1.000	.016	4	view →
HNSC	DFS	Tertile	II,III,IV	1.000	0.930	.038	3	view →
LSCC	OS	Quartile	All	0.711	0.968	.004	3	view →
UCEC	DFS	Quartile	All	0.975	0.842	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PHLDA3–CCRCC (OS)

Open the CCRCC breakdown →